InvenireX Advances Early Detection through Nano Technology

InvenireX acquires new financing to enhance its DNA-based nano technology platform in the early and accurate detection of tumors.

Biotech startup InvenireX has raised £2 million in seed funding to fast-track the development of its DNA-based nano technology platform, which is aimed at ultra-early tumor detection. DSW Ventures was the first manager to raise the round and XTX Ventures and Cambridge Technology Capital followed, which the second investment milestone the company is reached since the previous year when it raised £500,000.

The firm will be trying to resolve the long-term issues in the search for biological markers; this is one area that the traditional technologies such as PCR may not perform well because it is a complex process that is likely to lose important molecular cues. The DNA nanostructures, called nanites, are programmable and designed to be positioned in the heart of the next-generation nano technology solution of InvenireX.

These nanites can be integrated into custom microfluidic chips and capture genetic markers with increased specificity, and an AI-based reader can then identify and quantify targets extremely fast. This is in stark contrast with the conventional processes of molecular detection that may be slow and unreliable.

Founder and CEO Dan Todd has claimed the platform is a needle-in-a-haystack detector and can detect small mistakes in the DNA before the symptoms occur. The company claims that the uses of its nano technology are not limited to oncology; the technology can be used in vaccine validation as well as to discover hard-to-detect biological markers that are important in research.

InvenireX purports that the system may pick up tumors as small as one millimeter away up to ten years before the existing technology indicates another big breakthrough in the field of DNA nano technology and targeted medicine.